Tcr2 Therapeutics Inc (NASDAQ:TCRR) Short Interest Up 209.8% in July

Tcr2 Therapeutics Inc (NASDAQ:TCRR) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 626,700 shares, a growth of 209.8% from the June 30th total of 202,300 shares. Based on an average daily volume of 50,700 shares, the short-interest ratio is currently 12.4 days. Approximately 7.5% of the company’s shares are sold short.

Shares of TCRR stock traded up $0.81 during trading hours on Monday, reaching $16.09. 31,767 shares of the stock were exchanged, compared to its average volume of 49,381. The stock has a fifty day moving average price of $14.13. Tcr2 Therapeutics has a 12-month low of $10.04 and a 12-month high of $25.47. The stock has a market cap of $375.86 million and a price-to-earnings ratio of -0.16.

Tcr2 Therapeutics (NASDAQ:TCRR) last released its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.11. Equities analysts predict that Tcr2 Therapeutics will post -6.12 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of TCRR. Charles Schwab Investment Management Inc. acquired a new position in Tcr2 Therapeutics during the second quarter valued at $349,000. Laurion Capital Management LP purchased a new position in shares of Tcr2 Therapeutics during the first quarter worth approximately $417,000. Dean Capital Investments Management LLC purchased a new position in shares of Tcr2 Therapeutics during the first quarter worth approximately $694,000. Redmile Group LLC purchased a new position in shares of Tcr2 Therapeutics during the first quarter worth approximately $28,686,000. Finally, MPM Asset Management LLC purchased a new position in shares of Tcr2 Therapeutics during the first quarter worth approximately $67,192,000. 33.26% of the stock is currently owned by hedge funds and other institutional investors.

TCRR has been the subject of a number of recent analyst reports. Roth Capital initiated coverage on Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 price target for the company. Zacks Investment Research upgraded Tcr2 Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Finally, ValuEngine upgraded Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Tcr2 Therapeutics presently has an average rating of “Buy” and an average price target of $27.80.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: Bar Chart

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit